key: cord-0726229-8n6aj2ob
authors: Henriquez, S.; Zerbit, J.; Bruel, T.; Ouedrani, A.; Planas, D.; Deschamps, P.; Staropoli, I.; Hadjadj, J.; Varet, B.; Ermak, N.; Bouscary, D.; Willems, L.; Fouquet, G.; Decroocq, J.; Franchi, P.; Deau-Fischer, B.; Terrier, B.; Tamburini, J.; Chatenoud, L.; Schwartz, O.; Vignon, M.
title: Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients
date: 2021-12-16
journal: Blood
DOI: 10.1182/blood.2021013714
sha: ca3b7d7908960611c4b5b91e8006a32c1e3432e8
doc_id: 726229
cord_uid: 8n6aj2ob

nan

Multiple myeloma (MM) is considered as a high-priority condition for vaccination against SARS-CoV-2 39 1 . Uncertainties exist regarding the immune response to vaccine 2 . Since high titers of neutralizing 40 antibodies (NAbs) are necessary to inhibit delta variant 3 , patients with impaired immune response 41 may be at risk of breakthrough infection. We prospectively investigated the humoral and cellular 42 immunological response to anti-SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) in MM 43 patients on-therapy, or in whom treatment was discontinued within 12 months, from January 44 2021 at a single tertiary-care institution in Paris. 45

Among 72 consecutive MM patients, 11 had a previous SARS-CoV-2 infection history. At the time of 46 vaccination, 48 patients were treated with anti-CD38 immunotherapy-based regimen (anti-CD38 47 group), and 24 patients were not (non-anti-CD38 group) ( Figure 1A) . These two groups were well-48 balanced for several variables including age, gender, international staging system (ISS) score, high-49 risk cytogenetics, disease duration, autologous hematopoietic stem cell transplantation (ASCT) 50 history and concurrent IMIDs and/or proteasome inhibitors therapy. However, patients receiving 51

anti-CD38 therapy had more treatment lines, were more frequently remote from ASCT and had lower 52 γ-globulins levels compared the non-anti-CD38 patients (Table S1 ). Serum samples were collected 53 the day before vaccination (T0), before the second dose (M1) and one to two months after 54 completion of vaccination (M3) -see supplemental methods. An informed signed consent was 55 obtained from each patient in agreement with the declaration of Helsinki. We measured the 56 production of anti-Spike (S) immunoglobulins (IgG and IgA) and NAbs against Alpha (B.1.1.7) and 57

Delta (B.1.617.2) variants using S-Flow and S-Fuse neutralization assays, respectively 4,5 . Moreover, 58

we quantified the proportion of SARS-CoV-2-specific IFNγ-producing T-cells ex vivo among patient 59 samples by EliSpot after stimulation with S1 and S2 antigen at M3. Results obtained from MM patient 60 samples were compared with those obtained from 23 healthy volunteers (control group; median age 61 53, range 25-73). 62

First, we focused our analysis on MM patients without SARS-CoV-2 infection history (n=60), and 63 observed that only 44% and 85% of them achieved IgG seroconversion at M1 and M3, respectively, 64 as compared to 100% among the control group ( Figure S1A) . Moreover, IgG and IgA titers were 65 significantly lower at M1 in MM patients, and remained lower for IgA at M3 compared to the control 66 group ( Figure 1B) . Next, we observed lower IgG, but similar IgA in MM patients receiving anti-CD38 67 compared to those receiving alternative treatments ( Figure 1C and S1B). To assess the protection 68 agains SARS-CoV-2, we measured the production of NAbs against alpha and delta variants. NAbs 69 response was significantly higher against the alpha variant, but we observed a strong correlation 70 between alpha and delta response across MM patients ( Figure S1C-D) . While all subjects in the 71 control group developed NAbs against both variants after vaccination, only 51% and 41% of MM 72 patients developed NAbs against alpha and delta variants, respectively, and alpha and delta NAbs 73 titers were significantly lower in MM patients compared to controls ( Figure 1D ). Among MM 74 patients, anti-CD38 therapy further reduced NAbs production against alpha variant, with a near-75 significant trend for the delta variant ( Figure 1E ). In MM patients, we observed a low correlation 76 between anti-S IgG or IgA and anti-alpha or -delta NAbs production, particularly due to patients 77 developing IgG or IgA, but not NAbs ( Figure S1E ). 78

We investigated the day-21 humoral response in 16 MM patients of the anti-CD38 group who 79 received a third BNT162b2 dose at least 21 days after the second ("booster" protocol), and observed 80 an improvement of the S-response in half of patients having achieved seroconversion to the second 81 dose (BU>0,6) and a significant increase of IgG titres in patients with suboptimal response (BU<0,6) 82 ( Figure S2A) . However, no significant improvement of alpha or delta NAbs response was observed 83 even if increased NAbs were observed in some patients ( Figure S2B) . 84

Finally, we observed that an absence of neutralizing response against alpha and delta variants after 85 the second dose was significantly associated with progressive disease, number of treatment lines and 86 lower γ-globulin levels, and that anti-CD38 therapy was associated with failure to generate NAbs 87 (Table S2) . However, none of these variables retained statistical significance after multivariate 88 analysis, possibly due to the limited number of patients included and to interactions between 89 considered variables. As MM patients treated or not with anti-CD38 received IMIDs or PI in similar 90

proportion, our results suggests that impaired immune response to SARS-CoV-2 vaccine is favored by 91 targeting non-malignant B-cells, as reported in patient receiving anti-CD20 antibodies 6-8 . 92

We investigated post-vaccine anti-SARS-CoV-2 T-cell response in 26 MM patients from our cohort, 93

including 24 receiving anti-CD38 therapy, and in 21 healthy volunteers three month after the first 94 dose of BNT162b2. The IFNγ production by T-cells after S1 or S2 antigen stimulation ex vivo was 95 significantly lower in MM patients, compared to healthy SARS-CoV-2-naive controls ( Figure 1F ). 96

Among 26 MM patients tested for cellular response, 12 (46%) lacked NAbs and IFNγ production, 5 97 (19%) developed both humoral and cellular response and 9 (35%) showed heterogeneous results 98 ( Figure S3) . Notably, all controls had both NAbs and specific T-cell response after BNT162b2 (data not 99

shown). These results show an altered cellular response to anti-SARS-CoV-2 vaccine in MM patients. 100

Next, we studied the immune response to BNT162b2 dependent on SARS-CoV-2 infection history. 101 First, we observed higher anti-S IgG levels in MM patients with history of SARS-CoV-2 infection 102 before (n=11) or after (n=4) vaccination compared to other patients, without difference regarding 103 the timing of infection and vaccination (Figure 2A) . Similarly, MM patients with SARS-CoV-2 infection 104 had higher alpha and delta specific NAbs levels, and T-cell IFNγ response compared to those without 105 infection (Figures 2B-C) . 106 Among our cohort of 60 SARS-CoV-2-naive MM patients, four developed an infection after one (n=2) 107 or two doses (n=2) of BNT162b2, and all were receiving anti-CD38 immunotherapy ( Figure 1A) . We 108 retrospectively recorded SARS-CoV-2-related mortality from January 2020 to July 2021 in 39 Paris 109 public hospitals using the Informatics for Integrated Biology and the Bedside (i2b2) platform. When 110 comparing two epidemic peaks periods (March-July 2020 and 2021), the number of SARS-CoV-2-111 related death remained stable or tended to decrease in MM patients receiving or not anti-CD38 112 immunotherapy, respectively, even though anti-CD38 prescriptions volume remained stable ( Figure  113  S4A-B) . While several bias could have occurred in this retrospective multisite analysis, these results 114 along with our observations in a small cohort suggest that impaired vaccine response in patients 115 receiving anti-CD38 could have clinical implications that should be investigated prospectively. 116

In contrast to observations made among healthy populations 3,9 , correlation between the commonly-117 used S-Flow antibody titration technique and the detection of NAbs was weak in MM patients, 118

suggesting a low predictive value of serology in terms of protection. Moreover, emergence of SARS-119

CoV-2 variants with lower response to vaccination, such as the delta variant is particularly 120 problematic for individuals with sub-optimal vaccine response 3,10 . In agreement with recent reports, 121

we observed heterogeneous humoral response to vaccine in SARS-CoV-2-naive MM patients 11 . MM 122 patients treated with anti-CD38 immunotherapy remain at higher risk of SARS-CoV-2 infection after 123 mRNA-based vaccination compared to patients receiving alternative therapies 12 . In contrast, MM 124 patients developing SARS-CoV-2 infection before or after vaccination had homogeneous and robust 125 immune response. Our preliminary results on booster vaccine also suggest that immune response to 126 SARS-CoV-2 remains actionable in MM patients. Improvement of vaccine formulation such as 127 adjuvant use or heterologous vaccination procedure 13 could be considered in this frail population. 128 

Statements for vaccination against COVID-19 in patients with cancer

Low titers of SARS-CoV-2 neutralizing antibodies after first 157 vaccination dose in cancer patients receiving checkpoint inhibitors

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 160 neutralization

A comparison of four serological assays for detecting 162 anti-SARS-CoV-2 antibodies in human serum samples from different populations

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 165 variants to neutralizing antibodies

but not other antirheumatic therapies, is associated 167 with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic 168 diseases

SARS-CoV-2 vaccination in rituximab-170 treated patients: evidence for impaired humoral but inducible cellular immune response. Annals 171 of the Rheumatic Diseases

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in 173 patients with cancer

mRNA vaccination boosts cross-variant neutralizing 175 antibodies elicited by SARS-CoV-2 infection

Protective activity of mRNA vaccines against ancestral 177 and variant SARS-CoV-2 strains. bioRxiv

Highly variable SARS-CoV-2 spike antibody responses to 179 two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Fifth-week immunogenicity and safety of anti

CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies 183 on active treatment: preliminary data from a single institution

Immune responses against SARS-CoV-2 186 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

The authors first would like to thank the patients and the healthy volunteers who 129 participated in this study. We are very grateful to all nurses, technicians and physicians from Groupe 130Hospitalo-Universitaire AP-HP.Centre-Université de Paris involved in the daily care of the patients 131 included or not in this study, who have gone far beyond their usual jobs during this epidemic.